Meeting Coverage

Meeting Coverage

Updates from major medical meetings in the field of hematology/oncology

On location

Tagraxofusp: A New Option for Blastic Plasmacytoid Dendritic Cell Neoplasm?

Treatment with tagraxofusp, an anti-CD123 targeted agent previously known as SL-401, appeared to be safe and effective for managing blastic plasmacytoid dendritic cell neoplasm...
On location

CheckMate 205: Evaluating Nivolumab in Newly Diagnosed Hodgkin Lymphoma

In a study presented by Radhakrishnan Ramchandren, MD, at the 23rd Congress of the European Hematology Association, the four-drug regimen of nivolumab plus doxorubicin,...
On location

Better Together: IDH Inhibitors Plus Azacitidine in Newly Diagnosed AML

Results from a phase Ib/II study presented at the 23rd Congress of the European Hematology Association suggest that combining an IDH inhibitor (ivosidenib or...
On location

Cardiac Biomarkers Predict Quality of Life in Patients With Light-Chain Amyloidosis

In a study presented at the 23rd Congress of the European Hematology Association, researchers demonstrated a relationship between B-type natriuretic peptide (BNP) and N-terminal...
On location

Bispecific Antibody AMV564 Active in Relapsed and Refractory AML

Treatment with the CD33/CD3 bivalent, bispecific antibody AMV564 demonstrated clinical activity in patients with relapsed and refractory acute myeloid leukemia (AML) with a tolerable...
On location

Combining Ibrutinib and Venetoclax Produces High MRD-Negative Rates in Treatment-Naïve CLL

The all-oral regimen of single-agent ibrutinib followed by combined ibrutinib and venetoclax increased the odds that patients with treatment-naïve chronic lymphocytic leukemia (CLL) will...
On location

Updated Results from JULIET: Tisagenlecleucel Associated With Durable Responses in DLBCL

In May 2018, the U.S. Food and Drug Administration expanded the approval of the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel to the treatment...
On location

Obinutuzumab Beats Rituximab in Older Patients With CLL

Treatment with obinutuzumab plus chlorambucil led to greater improvements in progression-free survival (PFS) and overall survival (OS) than the combination of rituximab and chlorambucil,...
On location

Higher-Dose Daunorubicin No More Effective Than Lower Doses in AML

Escalating daunorubicin doses from 60 mg/m2 to 90 mg/m2 in a 7+3 induction regimen consisting of daunorubicin and cytarabine did not increase response rates...
On location

Axicabtagene Ciloleucel Moves to Acute Lymphocytic Leukemia

Axicabtagene ciloleucel, which in October 2017 became the first chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of B-cell lymphoma, showed “promising...
Advertisement

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.